Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3419230 | 0.88 | ESR1 (0.69) | ESR1ESR2 | |
| SCHEMBL3416253 | 0.88 | ESR1 (0.69) | ESR1ESR2 | |
| SCHEMBL4157960 | 0.87 | ESR1 (0.55) | ESR1ESR2 | |
| SCHEMBL4160287 | 0.86 | ESR1 (0.58) | ESR1ESR2 | |
| SCHEMBL4160094 | 0.85 | ESR1 (0.60) | ESR1ESR2 | |
| SCHEMBL12939126 | 0.83 | ESR1 (0.53) | ESR1ESR2 | |
| SCHEMBL30782456 | 0.83 | ESR1 (0.57) | ESR1ESR2 | |
| SCHEMBL4447857 | 0.82 | ESR1 (0.61) | ESR1ESR2 | |
| SCHEMBL4143432 | 0.82 | ESR1 (0.60) | ESR1ESR2 | |
| SCHEMBL4164188 | 0.82 | ESR1 (0.49) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329784-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS | WYETH LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8815934-B2 | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations | WYETH LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20120252769-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS | WYETH LLC (US) | 2012-10-04 | — | — | US | disclosed |
| US-20090176764-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLES AS ESTROGENIC AGENTS | WYETH (US) | 2009-07-09 | — | — | US | disclosed |
| US-7449455-B2 | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | WYETH (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080021017-A1 | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | WYETH (US) | 2008-01-24 | — | — | US | disclosed |
| US-7247624-B2 | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | WYETH (US) | 2007-07-24 | — | — | US | disclosed |
| US-20070142361-A1 | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations | WYETH (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070135397-A1 | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations | WYETH (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135396-A1 | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations | WYETH (US) | 2007-06-14 | — | — | US | disclosed |
| EP-0802183-B1 | Estrogenic agents | AMERICAN HOME PROD (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6291451-B1 | USEFUL IN THE TREATMENT OR INHIBITION OF BREAST CANCER. | AMERICAN HOME PRODUCTS CORPORATION | 2001-09-18 | — | — | US | disclosed |
| US-20010021719-A1 | 2-phenyl-1- [4- (2-aminoethoxy) - benzyl] - indoles as estrogenic agents | WYETH | 2001-09-13 | — | — | US | disclosed |
| US-6232307-B1 | 2-PHENYL-1-(4-(2-AMINOETHOXY)-BENZYL)-INDOLE COMPOUNDS USEFUL AS ESTROGENIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION | 2001-05-15 | — | — | US | disclosed |
| US-6225308-B1 | 2-PHENYL-1-(4-(2-AMINOETHOXY)-BENZYL)-INDOLE COMPOUNDS WHICH ARE USEFUL AS ESTROGENIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION | 2001-05-01 | — | — | US | disclosed |
| EP-1076558-A1 | 2-PHENYL-1-[-(2-AMINOETHOXY)-BENZYL -INDOLE IN COMBINATION WITH ESTROGENS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-21 | — | — | EP | disclosed |
| US-6127404-A | 2-PHENYL-1-(4-(2-AMINOETHOXY)-BENZYL)INDOLE COMPOUNDS USEFUL AS ESTROGEN AGONISTS/ANTAGONISTS; OSTEOPOROSIS; ANTICHOLESTEROL AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| US-5998402-A | OSTEOPOROSIS; CARDIOVASCULAR DISORDERS; ANTICANCER AGENTS;POSTMEMOPAUSE THERAPY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1999059581-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE IN COMBINATION WITH ESTROGENS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-25 | — | — | WO | disclosed |
| EP-0802183-A1 | Estrogenic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021719-A1 | 2-phenyl-1- [4- (2-aminoethoxy) - benzyl] - indoles as estrogenic agents | ESR1, ESR2, GPER1 | ESR1 1/4885ESR2 2/4885 |
| US-20140329784-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS | ESR2, ESR1, CYP19A1 | ESR1 2/4885ESR2 1/4885 |
| US-20120252769-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS | ESR2, ESR1, CYP19A1 | ESR1 2/4885ESR2 1/4885 |
| US-20070135397-A1 | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations | ESR2, ESR1, CYP19A1 | ESR1 2/4885ESR2 1/4885 |
| US-20070135396-A1 | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations | ESR2, ESR1, CYP19A1 | ESR1 2/4885ESR2 1/4885 |
| US-20070142361-A1 | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations | ESR1, ESR2, CYP19A1 | ESR1 1/4885ESR2 2/4885 |
| US-20090176764-A1 | 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLES AS ESTROGENIC AGENTS | BRCA1, ESR2, PKD2 | ESR1 5/4885ESR2 2/4885 |
| US-20080021017-A1 | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | BRCA1, PKD2, CYP19A1 | ESR1 5/4885ESR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.